高脂血症的外科治疗项目：一份现状报告。
The Program on the Surgical Control of the Hyperlipidemias: a status report.
作者信息
Buchwald H, Moore R B, Matts J P, Long J M, Varco R L, Campbell G S, Pearce M B, Yellin A E, Blankenhorn D H, Holmes W L, Smink R D, Sawin H S
出版信息
Surgery. 1982 Oct;92(4):654-62.
The Program on Surgical Control of the Hyperlipidemias (POSCH) is a multicentered secondary coronary heart disease intervention trial utilizing maximal plasma lipid reduction as achieved by the partial ileal bypass operation. With over 500 patients recruited into this trial at present, the 4-year sequential lipid changes are statistically highly significant and include an approximate 30% plasma total cholesterol and 40% low density lipoprotein (LDL)-cholesterol reduction, with a slight increase in the high density lipoprotein (HDL)-cholesterol and a marked increase in the HDL-cholesterol:LDL-cholesterol ratio of about 75% or higher. A definitive answer to the lipid-atherosclerosis theory corollary--whether a decrease in the plasma cholesterol engenders a reduction in the incidence or severity of atherosclerotic cardiovascular disease--can be expected from these marked lipid changes in POSCH.
高脂血症外科治疗项目（POSCH）是一项多中心继发性冠心病干预试验，采用部分回肠旁路手术实现最大程度的血浆脂质降低。目前已有500多名患者参与该试验，4年的连续脂质变化在统计学上具有高度显著性，包括血浆总胆固醇降低约30%，低密度脂蛋白（LDL）胆固醇降低40%，高密度脂蛋白（HDL）胆固醇略有增加，HDL胆固醇与LDL胆固醇的比值显著增加约75%或更高。从POSCH中这些显著的脂质变化中，可以期待得到关于脂质-动脉粥样硬化理论推论的明确答案，即血浆胆固醇的降低是否会导致动脉粥样硬化性心血管疾病的发病率或严重程度降低。
Zotero 插件